EntryPoint Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
Other funds holding AUPH
TCM
NMC
EntryPoint Capital's AUPH Position: Q2 2026 in Review
EntryPoint Capital increased its Aurinia Pharmaceuticals (AUPH) stake by 276% in Q2 2026, buying an estimated $565K and bringing the position to 48,218 shares worth $818K. The position accounts for 0.2% of the portfolio, ranked #135.
EntryPoint Capital first reported a position in AUPH in Q4 2023 and has held it in 8 quarters since. The position peaked at $857K in Q2 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.
- EntryPoint Capital held 48,218 shares of Aurinia Pharmaceuticals worth $818K as of Q2 2026.
- EntryPoint Capital bought 35,377 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $565K.
- Aurinia Pharmaceuticals made up 0.2% of EntryPoint Capital's portfolio in Q2 2026, its #135 holding.
- EntryPoint Capital first reported a position in Aurinia Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
- EntryPoint Capital's Aurinia Pharmaceuticals position peaked at $857K in Q2 2025.
- 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.